DDInter1834 DDInter833
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults. Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass accounted for by oxygen. Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Topiramate {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Glycerol phenylbutyrate
Topiramate {u} (Compound) treats {v} (Disease) obesity
obesity {u} (Disease) is associated with {v} (Gene) PNLIP
PNLIP {u} (Gene) is bound by {v} (Compound) Glycerol phenylbutyrate
Topiramate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Glycerol phenylbutyrate (Compound)
Topiramate (Compound) treats obesity (Disease) and obesity (Disease) is associated with PNLIP (Gene) and PNLIP (Gene) is bound by Glycerol phenylbutyrate (Compound)